{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CART19",
    "query": {
      "condition": "CART19"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CART19&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T22:11:34.198Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02445248",
      "title": "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Tisagenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lymphodepleting chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2015-07-29",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 12,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02445248"
    },
    {
      "nct_id": "NCT01747486",
      "title": "Dose Optimization Trial of CD19 Redirected Autologous T Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL"
      ],
      "interventions": [
        {
          "name": "CART-19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2013-01-02",
      "completion_date": "2018-04-06",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01747486"
    },
    {
      "nct_id": "NCT01551043",
      "title": "Allo CART-19 Protocol",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CART-19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2010-09",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01551043"
    },
    {
      "nct_id": "NCT06839976",
      "title": "CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SLE",
        "Systemic Lupus Erythematosus (SLE)",
        "CAR T Cell",
        "CART19",
        "Cell Therapy",
        "Lupus",
        "Lupus Nephritis (LN)"
      ],
      "interventions": [
        {
          "name": "CART19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "12 Years to 29 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-05-06",
      "completion_date": "2030-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06839976"
    },
    {
      "nct_id": "NCT01626495",
      "title": "Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B Cell Leukemia",
        "B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CART-19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "1 Year to 24 Years"
      },
      "enrollment_count": 73,
      "start_date": "2011-08-17",
      "completion_date": "2019-07-11",
      "has_results": true,
      "last_update_posted_date": "2020-03-23",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01626495"
    },
    {
      "nct_id": "NCT01029366",
      "title": "CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematopoietic/Lymphoid Cancer",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "B-cell Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CART-19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2010-03-17",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01029366"
    },
    {
      "nct_id": "NCT02640209",
      "title": "Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)"
      ],
      "interventions": [
        {
          "name": "CART 19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-01-29",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02640209"
    },
    {
      "nct_id": "NCT02935543",
      "title": "CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Acute Lymphoblastic"
      ],
      "interventions": [
        {
          "name": "CART 19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-10",
      "completion_date": "2018-12-12",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935543"
    },
    {
      "nct_id": "NCT04276870",
      "title": "Orphan Indications for CD19 Redirected Autologous T Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL",
        "Infants With Very High Risk KMT2A B-ALL",
        "Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation"
      ],
      "interventions": [
        {
          "name": "Murine CART19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stephan Grupp MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "0 Years to 29 Years"
      },
      "enrollment_count": 133,
      "start_date": "2020-03-12",
      "completion_date": "2037-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276870"
    },
    {
      "nct_id": "NCT02476734",
      "title": "FDG-PET/CT Imaging as Early Predictor of DP",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "There is no intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2014-08",
      "completion_date": "2018-08",
      "has_results": false,
      "last_update_posted_date": "2023-07-11",
      "last_synced_at": "2026-06-25T22:11:34.198Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02476734"
    }
  ]
}